For those of you who would like to use the new Reporting of Setting in Psychedelic Clinical Trials (ReSPCT) guidelines, we’ve created a user-friendly website to help you navigate the guidelines: 👉 Wesbite: https://t.co/BRLEGW3p5h 👉 Paper: https://t.co/2T0vsHO3Pz On the site,

Psychedelic researchers establish new ReSPCT guidelines, emphasizing crucial environmental factors for improved clinical trial reporting and methodology. by Pronovost-Morgan C, Greenway KT and Roseman L in Nat Med https://t.co/NwlxCngRm3 #MedX #MedResearch

🚨🍄 Major new preprint alert 🍄🚨 I think these will be important results. They are not going make me popular with my #psychedelic in-group, please do not shoot the messenger! The premise of this pre-registered meta analysis ( https://t.co/1V8sphbh0c) is that it is biased to

A great step toward standardizing reporting of extrapharmacologic factors in psychedelic trials! Congrats @ChloePronovostM @LeorRoseman et al

As psychedelics gain traction as potential treatments for mental health disorders, an international study co-led by @mcgillu researchers stands to improve the rigour and reliability of clinical research. https://t.co/DSaGRuG4x8

New in @NatureMedicine: ReSPCT "An international Delphi consensus for reporting of setting in psychedelic clinical trials" by @ChloePronovostM, Kyle Greenway, myself, and many ReSPCT Experts. "The ReSPCT guidelines and accompanying explanatory document provide a new standard for

Immensely excited by the publication of “The mindful use of psychiatric medication,” a new and groundbreaking paper that demonstrates how the the concept of set and setting can be integrated into psychiatric care to improve safety, satisfaction and efficacy while reducing abuse

Drug X Context, instead of Drug + Context Psychedelics ARE NOT the new paradigm, but the anomaly which questions the old paradigm An interactive paradigm is relevant to all psychoactive drugs A lot is at risk here - including the RCT as we know it https://t.co/73YeUpIlI7